Mechanisms of Trastuzumab Resistance and Their Clinical Implications
- 1 November 2005
- journal article
- review article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1059 (1) , 70-75
- https://doi.org/10.1196/annals.1339.026
Abstract
Trastuzumab (Herceptin) is an excellent model of rationally designed targeted cancer treatment. However, less than 35% of patients with ErbB2-positive breast tumors respond to trastuzumab as a single agent, and 2-5% of trastuzumab-treated patients suffer from severe side effects, including cardiac dysfunction. Recent progress in understanding the mechanisms of trastuzumab antitumor function and cellular defects leading to trastuzumab resistance is summarized. Also explored is the potential of combination therapies for reversing trastuzumab resistance.Keywords
This publication has 24 references indexed in Scilit:
- Targeted Therapies for Cancer 2004American Journal of Clinical Pathology, 2004
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- Molecular mechanisms underlying IGF‐I‐induced attenuation of the growth‐inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cellsInternational Journal of Cancer, 2003
- Combined trastuzumab and paclitaxel treatment better inhibits ErbB‐2‐mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment aloneCancer, 2003
- Phosphorylation on Tyrosine-15 of p34Cdc2 by ErbB2 Inhibits p34Cdc2 Activation and Is Involved in Resistance to Taxol-Induced ApoptosisMolecular Cell, 2002
- Herceptin acts as an anti-angiogenic cocktailNature, 2002
- Overexpression of ErbB2 in cancer and ErbB2-targeting strategiesOncogene, 2000
- Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancersNature Genetics, 1997
- PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate CancerScience, 1997
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987